登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
The Efficacy and Safety of Trastuzumab Rezetecan (SHR-A1811) in HER2-Low Unresectable/Metastatic Breast Cancer Patients With Visceral Crisis
ClinicalTrials.gov 上登记的一项乳腺癌开放试验,由中国医学科学院肿瘤医院牵头,本站收录的另外 0 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 1
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT07203729,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 5
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(5 项)收起清单
18 岁 至 75 岁;性别:仅女性
登记记录的入选字段
Pathologically confirmed HER2-Low unresectable or metastatic breast cancer;
入选标准第 2 条
Patients who have received ≤ 3 line of chemotherapy in the advanced stage are permitted.
入选标准第 6 条
Previous treatment with CDK4/6 inhibitors is permitted.
入选标准第 8 条
Are pregnant or lactating women, or women of childbearing age who are unwilling to use effective contraceptive measures throughout the trial period and within 7 months after the last administration of the study drug.
排除标准第 10 条
Have had other malignant tumors within the past 5 years, excluding cured carcinoma in situ of the cervix, cutaneous basal cell carcinoma, or cutaneous squamous cell carcinoma (patients with other malignant tumors that occurred more than 5 years before randomization and were cured solely by surgery are eligible for enrollment).
排除标准第 3 条
Have a history of immunodeficiency, including HIV infection, or other acquired or congenital immunodeficiency diseases.
排除标准第 7 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:日常活动能力;化验:血常规、肝肾功能;影像与可测量病灶;怀孕、哺乳与避孕。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07203729,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
Age: ≥18 years old and ≤75 years old; Pathologically confirmed HER2-Low unresectable or metastatic breast cancer; Investigator-assessed visceral crisis. Visceral crisis includes clinical crisis and molecular crisis. Subjects must meet the criteria for either clinical crisis or molecular crisis. Patients whom investigators deem to have indications for single-agent chemotherapy. Sufficient bone marrow function, defined as follows:a) Neutrophil count (ANC) ≥ 1,500/mm³ (1.5 × 10⁹/L);b) Platelet count (PLT) ≥ 80 ×10\^9/L;c) Hemoglobin (Hb) ≥ 80 g/L; Patients who have received ≤ 3 line of chemotherapy in the advanced stage are permitted. Patients who have received endocrine therapy in the advanced stage are permitted. Previous treatment with CDK4/6 inhibitors is permitted. Previous or concurrent local treatment for symptom relief is permitted. For female subjects who are premenopausal or not surgically sterilized: Patients must voluntarily participate in this study, sign the informed consent form, have good compliance, and be willing to cooperate with follow-up.排除标准:Exclusion Criteria:
Have received treatment with new antibody-drug conjugates (ADCs) at any stage of breast cancer. Are deemed by the investigator as unsuitable for systemic chemotherapy. Have had other malignant tumors within the past 5 years, excluding cured carcinoma in situ of the cervix, cutaneous basal cell carcinoma, or cutaneous squamous cell carcinoma (patients with other malignant tumors that occurred more than 5 years before randomization and were cured solely by surgery are eligible for enrollment). Have undergone major surgical procedures or suffered significant trauma within 4 weeks prior to randomization, or are expected to undergo major surgical treatment. Have severe heart disease or cardiac discomfort, including but not limited to the following conditions:a) A history of heart failure or systolic dysfunction (left ventricular ejection fraction [LVEF] < 50%);b) High-risk angina pectoris requiring treatment or cardiac arrhythmias;c) Clinically significant valvular heart disease;d) ECG findings indicating transmural myocardial infarction;e) Poorly controlled hypertension. Have a known history of allergy to any component of the drugs in this protocol. Have a history of immunodeficiency, including HIV infection, or other acquired or congenital immunodeficiency diseases. Have a known history of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation. Have a known history of psychotropic substance abuse or drug addiction. Are pregnant or lactating women, or women of childbearing age who are unwilling to use effective contraceptive measures throughout the trial period and within 7 months after the last administration of the study drug. Have severe diseases, other comorbidities that would interfere with the planned treatment, or any other conditions that make them unsuitable for participation in this study (e.g., active hepatitis B, pulmonary infection requiring treatment).
引自 ClinicalTrials.gov, NCT07203729, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07203729,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。